Sign In
test

Anthony Cordone

Armistice Capital, Llc

Assets Managed
$5.624B
Holdings
253
Last Quarter
2026 - Q1
Filed Date
1mo ago
Growth Rate
-33.08%(2Q avg: -4.2%)
Sustained Growth
0 quarters

Portfolio positions

This chart displays the top 10 holdings in Armistice Capital, Llc's 2026 - Q1 portfolio, based on their 13F SEC filing, out of a total of 253 positions.

Assets under management

The assets under management (AUM) of Armistice Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2026 - Q1, they manage 5.624B in assets, with a quarterly growth rate of -33.08% and a 2-quarter average growth rate of -4.2%. The portfolio is managed by Anthony Cordone, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
SPY
Spdr S&p 500 Etf Trust
Recent Activity
Decreased -30%
24.29%
$1.366B↓ Put
2.1M shares@ $650.34 avg price
IWM
Ishares Russell 2000 Etf
Recent Activity
Decreased -56.79%
15.44%
$868M↓ Put
3.5M shares@ $248.0 avg price
AGIO
Agios Pharmaceuticals Inc
Recent Activity
Decreased -1.98%
3.56%
$200.138M
5.916M shares@ $33.83 avg price
CYTK
Cytokinetics Inc
Recent Activity
Increased 6.9%
3.13%
$175.62M
2.665M shares@ $65.92 avg price
PTCT
Ptc Therapeutics Inc
Recent Activity
Decreased -12.04%
2.99%
$167.903M
2.464M shares@ $68.13 avg price
TVTX
Travere Therapeutics Inc
Recent Activity
Increased 30.12%
2.59%
$145.502M
4.897M shares@ $29.71 avg price
MDGL
Madrigal Pharmaceuticals Inc
Recent Activity
Decreased -0.42%
2.47%
$138.501M
264,583 shares@ $523.47 avg price
IMVT
Immunovant Inc
Recent Activity
Decreased -15.88%
2.42%
$135.749M
5.465M shares@ $24.84 avg price
SUPN
Supernus Pharmaceuticals Inc
Recent Activity
Decreased -31.42%
1.75%
$97.97M
1.895M shares@ $51.69 avg price
NBIX
Neurocrine Biosciences Inc
Recent Activity
Decreased -11.73%
1.7%
$95.38M
724,000 shares@ $131.74 avg price

1-10 of 253